Editorial e603 A moment of reckoning The Lancet HIV +++...

Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trial Read this Article https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(25)00130-4/abstract?dgcid=raven_jbs_etoc_feature_lanhiv The clinical and economic impact of genotypic resistance testing for people diagnosed with persistent virological non-suppression on tenofovir–lamivudine–dolutegravir in South Africa: a modelling study Read this Article https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(25)00164-X/abstract?dgcid=raven_jbs_etoc_feature_lanhiv Editorial e603 A moment of reckoning The Lancet HIV https://www.thelancet.com/journals/lanhiv/issue/vol12no9/PIIS2352-3018(25)X0009-6